Fundz
Following Boston Oncology Arabia?

Get the free weekly contract digest

The latest new contracts, like Boston Oncology Arabia’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

BOSTON ONCOLOGY ARABIA and SPIMACO Partner to Localize Advanced Oral Oncology Treatments in Saudi Arabia

Jan 08, 2025•over 1 year ago

Contract Type

partnership

CambridgePharmaceutical

Description

BOSTON ONCOLOGY ARABIA and SPIMACO have signed a Memorandum of Understanding (MoU) to localize the production of advanced oral oncology treatments in Saudi Arabia. This partnership reflects a shared commitment to improving patient outcomes, fostering local expertise, and contributing to Saudi Arabia’s Vision 2030 goals for healthcare transformation.

Company Information

Company

Boston Oncology Arabia

Location

Cambridge, Massachusetts, United States

About

Bold and nimble, Boston Oncology is an innovative biogenerics company redefining excellence in the licensing and local development, manufacturing and distribution of US- quality medicines – across therapeutic areas. From our nerve center in Riyadh, we leverage the expertise, daring creativity, and unwavering determination of our international leadership team to provide customers with end-to-end, efficient, single-point-of-contact access to our diverse portfolio of world-class biogenerics.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Boston Oncology Arabia's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.